Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation

A Phase IIA Randomized, Double-Blind, Placebo-Controlled Study of LGD-4665 in Patients With Immune Thrombocytopenic Purpura (ITP) With an Open Label Extension

The purpose of this study is to assess the ability of LGD-4665 given daily by mouth to increase platelet counts in the treatment of patients with ITP (immune thrombocytopenic purpura). LGD-4665 increased platelet counts safely and tolerably compared to placebo in healthy volunteers. This study will examine the safety, tolerability and efficacy of 7.5 mg capsules of LGD-4665 to increase platelets compared to placebo, randomized 2:1, during blinded treatment for 6 weeks. Evaluation of platelet counts, bleeding scores and safety parameters will be done weekly. All patients are eligible to continue on active, open LGD-4665 treatment for an additional 12 weeks with optimal adjustment of dose for each patient.

Study Overview

• Status: Completed
• Conditions: Immune Thrombocytopenic Purpura
• Intervention / Treatment: Drug: Placebo; Drug: LGD-4665

Detailed Description

This is a Phase IIA study with two parts to the design.

• Part 1 is a randomized, double-blinded, placebo-controlled treatment of 7.5 mg/day LGD-4665 versus placebo in approximately 24 patients with ITP who have been treated with at least one prior therapy for ITP. Patients will be randomized in a ratio of 1:2 (placebo: 7.5 mg/day LGD-4665) for 6 weeks of treatment. Platelet counts, bleeding scores, vital signs, physical exams and laboratory tests will be assessed weekly. Treatment groups will be analyzed for efficacy by the percentage of patients with platelet counts two times baseline and ≥ 50,000/uL at 6 weeks of treatment, and for safety by adverse events, vital signs, physical exams, laboratory tests and use of ITP rescue medications or transfusions.
• Part 2 is an extension of study treatment with open label LGD-4665. All patients who participate in the Part 1 randomized double-blind treatment of this Ph IIA trial are eligible to continue open label treatment with LGD-4665 for up to 3 months at an appropriate dose for the safe maintenance of platelet counts (≥ 50,000/uL to ≤ 200,000/uL). Assessments of effectiveness and safety will be made at 2 and 4 week intervals.

• Study Type: Interventional
• Enrollment (Actual): 23
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • California
    • San Diego, California, United States, 92103-8409
      • University of California San Diego Medical Center
    • San Francisco, California, United States, 94143-1270
      • University of California, San Francisco
  • Connecticut
    • Manchester, Connecticut, United States, 06040
      • Davis, Posteraro and Wasser, MD's LLP
  • Florida
    • Jacksonville, Florida, United States, 32207
      • Baptist Cancer Institute
    • Orlando, Florida, United States, 32806
      • Cancer Center of Florida
  • Georgia
    • Atlanta, Georgia, United States, 30341
      • Georgia Cancer Specialists
  • Michigan
    • Detroit, Michigan, United States, 48202
      • Henry Ford Health System
    • Detroit, Michigan, United States, 48201
      • Karmanos Cancer Center, Wertz Clinical Cancer Center 4HWCRC
  • Missouri
    • Saint Louis, Missouri, United States, 63110
      • Washington University School of Medicine - St Louis, MO
  • New Mexico
    • Albuquerque, New Mexico, United States, 87109
      • New Mexico Oncology Hematology Consultants
  • New York
    • New York, New York, United States, 10029
      • Mount Sinai School of Medicine
    • New York, New York, United States, 10021
      • Joan and Sanford I. Weill Medical College, Cornell University
  • Ohio
    • Cleveland, Ohio, United States, 44106-7284
      • Case Western Reserve University School of Medicine
    • Cleveland, Ohio, United States, 44195
      • Cleveland Clinic Foundation, Univ. of Ohio
  • Texas
    • San Antonio, Texas, United States, 78229
      • Hematology Oncology Associates of South Texas

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Adults 18 years or older
• Diagnosis of ITP for at least 3 months consistent with ASH guidelines
• Treated with one or more prior therapies for ITP and platelet counts < 30,000/µL or < 50,000/µL if on a stable oral corticosteroid for ≥ 4 weeks, supported by 2 platelet counts in prior 30 days

• Laboratory results within normal range except for the following analytes

  • Hemoglobin ≥ 10 g/dL
  • Absolute neutrophil counts > 1000/mL
  • ALT ≤ 1.5X ULN
  • AST ≤ 1.5X ULN
  • Creatinine < 1.5X ULN
  • Bilirubin < 1.5X ULN
  • BUN < 1.5X ULN
  • PT < 1.5X ULN
  • aPTT <1.5X ULN
• Women of child-bearing potential must have a negative serum pregnancy test within 4 days prior to the first dose of study treatment and agree to practice an approved method of contraception or abstinence from sexual intercourse.
• Willing to sign a written informed consent

Exclusion criteria:

• History of heart attack or cardiovascular disease
• Known history of arterial or venous thrombosis
• More than 3 risk factors for thromboembolic events (diabetes, smoker, using oral contraception, using estrogen therapy, hypertriglyceridemia, average cholesterol > 240 mg/dL, treatment for hypertension)
• Active cancer or a history of bone marrow disorders
• Women who are pregnant or nursing
• History of alcohol/drug abuse or dependence within one year

• Listed medications dosed within:

  • 4 weeks of the first dose of the study treatment:

    • Use of Rituximab
    • Use of cytotoxic agents
    • Use of Cyclosporine and other immunomodulators
    • Use of an investigational drug

  • 2 weeks of the first dose of the study treatment:

    • Use of Danazol
    • Use of Azathioprine
    • Use of Mycophenolate mofetil and pulsed-dose steroids

  • 1 week of the first dose of the study treatment:

    • Use of Anti-D (WinRho®)
    • Use of IVIG
    • Had a platelet transfusion
    • Use of herbal/dietary supplements (excluding vitamins and mineral supplements)

  • 3 days of the first dose of the study treatment

    • Use of aspirin, aspirin containing compounds
    • salicylates
    • milk of magnesia
    • non-steroidal anti-inflammatory drugs (unless prescribed for heart disease)
• History of platelet aggregation that would prevent measurement of platelet counts
• Known active infection with HIV, hepatitis B, or hepatitis C
• In the Investigator's opinion, the patient is not able to comply with requirements of the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Drug: Placebo; Placebo
Experimental: LGD4665; LGD-4665: Experimental Thrombopoietin mimetic	Drug: LGD-4665; LGD-4665 Thrombopoietin mimetic

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of participants with platelet count >= 50000/µL	Response was defined as platelet count >= 50 x1000/uL for participants without Baseline steroid uses; or platelet counts >= 50 x1000/uL and doubling the Baseline platelet counts for participants with baseline steroid uses. Confidence interval of response rate was computed using exact method of binomial proportion.	At Week 6

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with time to response by Platelet Counts (platelet counts >= 50,000/µL)	Response was defined as platelet count >= 50 x1000/uL for participants without baseline steroid uses; or platelet counts >= 50 x1000/uL and doubling the Baseline platelet counts for participants with baseline steroid uses.	Week 1, 2, 4 and 6 of part 1
Change From Baseline to Last Bleeding Observation During Double-Blind Treatment	ITP Bleeding Severity Scale was used for the analysis of bleeding score. Bleeding scores were, 0=None, 1=minor, and 2=major. Body sites and bleeding grade analysis was as follows: cutaneous (1= 1-5 bruises; scattered petechiae and 2= > 5 bruises, >2 centimeter [cm]; petechiae), oral mucosa (1= 1 blood blister or > 5 petechiae, gum bleeding < 5 minute[min], 2= multiple blood blisters; gum bleeding > 5 min), epistaxis (1= blood on blowing nose or epistaxis < 5 min, 2= bleeding > 5 min), gastrointestinal (1= occult blood, 2= gross blood), gynecological (1= spotting not at time of period, 2= bleeding not at time of period or very heavy period), urinary (1= microscopic (+ by dipstick), 2= macroscopic), pulmonary(1= possible symptoms but mild, 2= yes), subconjunctival (1= yes, 2= both eyes significantly involved), Intracranial (1= possible symptoms, 2= yes, clinically confirmed). Change from Baseline was calculated as Baseline value minus post-randomization value. Baseline was Day 1value.	Day 1 (Baseline) and Week 6
Duration of platelet counts >= 50,000/µL of LGD4665	Response was defined as platelet count >= 50 x1000/uL for participants without baseline steroid uses; or platelet counts >= 50 x1000/uL and doubling the Baseline platelet counts.A Kaplan-Meier projection of time to response by platelet counts was analyzed.	Up to Week 6

Collaborators and Investigators

• Sponsor: GlaxoSmithKline

Study record dates

Study Major Dates

• Study Start (Actual): March 1, 2008
• Primary Completion (Actual): May 1, 2009
• Study Completion (Actual): May 1, 2009

Study Registration Dates

• First Submitted: February 12, 2008
• First Submitted That Met QC Criteria: February 21, 2008
• First Posted (Estimate): February 22, 2008

Study Record Updates

• Last Update Posted (Actual): January 18, 2018
• Last Update Submitted That Met QC Criteria: January 16, 2018
• Last Verified: January 1, 2018

More Information

Terms related to this study

• Keywords: thrombopoietin mimetic; Immune thrombocytopenic purpura; ITP
• Additional Relevant MeSH Terms: Pathologic Processes; Immune System Diseases; Autoimmune Diseases; Hematologic Diseases; Hemorrhage; Hemorrhagic Disorders; Blood Coagulation Disorders; Skin Manifestations; Thrombocytopenia; Blood Platelet Disorders; Thrombotic Microangiopathies; Purpura; Purpura, Thrombocytopenic; Purpura, Thrombocytopenic, Idiopathic
• Other Study ID Numbers: L4665-03